We are live on ! Find out more
PBLA

Panbela Therapeutics, Inc. Common Stock
PBLA

Delisted

PBLA was delisted on the 6th of March, 2024.

Back to rankings

10 hedge funds and large institutions have $564K invested in Panbela Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

685% more capital invested

Capital invested by funds: $71.8K → $564K (+$493K)

100% more funds holding

Funds holding: 5 → 10 (+5)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

Holders
10
Holders Change
+5
Holders Change %
+100%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$29.8K
2
Goldman Sachs
Goldman Sachs
New York
+$19.2K
3
JP Morgan Chase
JP Morgan Chase
New York
+$9.75K
4
TSS
Two Sigma Securities
New York
+$9.14K
5
TRCT
Tower Research Capital (TRC)
New York
+$7.5K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$1.28K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$449K +$19.2K +1,226 New
HF
2
HRT Financial
New York
$34K +$29.8K +1,907 New
Citadel Advisors
3
Citadel Advisors
Florida
$31.3K -$1.28K -82 -5%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$14.5K – – –
TRCT
5
Tower Research Capital (TRC)
New York
$13.7K +$7.5K +479 +176%
JP Morgan Chase
6
JP Morgan Chase
New York
$11.4K +$9.75K +623 New
TSS
7
Two Sigma Securities
New York
$10.7K +$9.14K +584 New
Osaic Holdings
8
Osaic Holdings
Arizona
$63 +$63 +4 New
Wells Fargo
9
Wells Fargo
California
$36 +$16 +1 +100%
Morgan Stanley
10
Morgan Stanley
New York
$18 – – –
Bank of America
11
Bank of America
North Carolina
$2 – – –

PBLA Hedge Fund Activity: Q4 2023 in Review

10 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Panbela Therapeutics, Inc. Common Stock (PBLA) for Q4 2023, worth a combined $564K — up 685% from $71.8K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new PBLA positions and 0 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $29.8K. The largest seller was Citadel Advisors, cutting an estimated $1.28K.

  • 10 institutional investors held Panbela Therapeutics, Inc. Common Stock (PBLA) as of Q4 2023, up from 5 in Q3 2023.
  • Funds reported $564K of Panbela Therapeutics, Inc. Common Stock stock for Q4 2023, up 685% quarter-over-quarter.
  • 5 funds opened new Panbela Therapeutics, Inc. Common Stock positions in Q4 2023 and 0 closed out, a net change of +5 holders.
  • The largest Panbela Therapeutics, Inc. Common Stock buyer in Q4 2023 was HRT Financial, an estimated $29.8K added.
  • The largest Panbela Therapeutics, Inc. Common Stock seller in Q4 2023 was Citadel Advisors, an estimated $1.28K sold.

Based on aggregated 13F filings for Q4 2023.